These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25750322)

  • 1. Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial.
    McGregor MJ; Fadhil W; Wharton R; Yanagisawa Y; Presz M; Pritchard A; Womack C; Dutton S; Kerr RS; Kerr DJ; Johnstone EC; Ilyas M
    Anticancer Res; 2015 Mar; 35(3):1641-5. PubMed ID: 25750322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
    Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
    J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
    Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
    J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.
    Williams DS; Mouradov D; Browne C; Palmieri M; Elliott MJ; Nightingale R; Fang CG; Li R; Mariadason JM; Faragher I; Jones IT; Churilov L; Tebbutt NC; Gibbs P; Sieber OM
    Mod Pathol; 2020 Mar; 33(3):483-495. PubMed ID: 31471586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
    Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
    BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.
    Wangefjord S; Brändstedt J; Lindquist KE; Nodin B; Jirström K; Eberhard J
    Diagn Pathol; 2013 Jan; 8():10. PubMed ID: 23337059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
    Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
    Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.
    Mouradov D; Domingo E; Gibbs P; Jorissen RN; Li S; Soo PY; Lipton L; Desai J; Danielsen HE; Oukrif D; Novelli M; Yau C; Holmes CC; Jones IT; McLaughlin S; Molloy P; Hawkins NJ; Ward R; Midgely R; Kerr D; Tomlinson IP; Sieber OM
    Am J Gastroenterol; 2013 Nov; 108(11):1785-93. PubMed ID: 24042191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of FUT8 expression in relation to p53 status in stage II and III colorectal cancer.
    Noda M; Okayama H; Kofunato Y; Chida S; Saito K; Tada T; Ashizawa M; Nakajima T; Aoto K; Kikuchi T; Sakamoto W; Endo H; Fujita S; Saito M; Momma T; Ohki S; Kono K
    PLoS One; 2018; 13(7):e0200315. PubMed ID: 29975776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer.
    Noske A; Lipka S; Budczies J; Müller K; Loddenkemper C; Buhr HJ; Kruschewski M
    Oncol Rep; 2009 Jul; 22(1):3-9. PubMed ID: 19513497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
    Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
    Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors.
    Schelwies K; Sturm I; Grabowski P; Scherübl H; Schindler I; Hermann S; Stein H; Buhr HJ; Riecken EO; Zeitz M; Dörken B; Daniel PT
    Int J Cancer; 2002 Jun; 99(4):589-96. PubMed ID: 11992551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.
    Thornton M; Aslam MA; Tweedle EM; Ang C; Campbell F; Jackson R; Costello E; Rooney PS; Vlatković N; Boyd MT
    Int J Cancer; 2013 Sep; 133(6):1408-18. PubMed ID: 23456958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma.
    Giatromanolaki A; Stathopoulos GP; Tsiompanou E; Papadimitriou C; Georgoulias V; Gatter KC; Harris AL; Koukourakis MI
    Cancer; 1999 Oct; 86(8):1421-30. PubMed ID: 10526268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Oh HJ; Bae JM; Wen X; Jung S; Kim Y; Kim KJ; Cho NY; Kim JH; Han SW; Kim TY; Kang GH
    Br J Cancer; 2019 Apr; 120(8):797-805. PubMed ID: 30894685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
    Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ
    BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VICTOR spoiled?
    Goldberg RM; Bertagnolli MM
    J Clin Oncol; 2010 Oct; 28(30):4546-8. PubMed ID: 20837951
    [No Abstract]   [Full Text] [Related]  

  • 20. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
    Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
    Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.